Celltrion applied for biosimilar trastuzumab in Japan

April 27, 2017 3:46 PM

Celltrion announced that the company submitted the application for sales approval to Japanese Ministry of Health, Labour and Welfare on 11th of April to enter the Japanese market for anticancer antibody biosimilar Herzuma(CT-P6, trastuzumab).

Herzuma is an anticancer antibody biosimilar used to treat breast cancer and gastric cancer. Its original product is ‘Herceptin’, which is developed and sold by Roche. The size of the original pharmaceutical market in Japan is estimated to be around 450 billion KRW, and Celltrion is aiming to launch in 2018 after approval of the sale of Herzuma.

Nippon kayaku, a partner for distribution of Herzuma, has maintained a strong partnership with Celltrion and has shown strength in the market for anticancers. Also, the company has sold Remsima of Celltrion, the first antibody biosimilar introduced to Japan, since the end of 2014, and has continued to increase market share steadily.

Celltrion official said “Celltrion, which is ready to hit the global market, including Europe, is responding closely to partner companies for Herzuma to settle early in Japanese market as well, When Herzuma is introduced to Japan, we expect positive effects on increasing market shares of Celltrion products including through enhancing awareness of the overall biosimilar.”

Source: Celltrion press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!